

How resistant are levodopa-resistant axial symptoms? Response of freezing, posture and voice to increasing levodopa intestinal infusion rates in Parkinson's disease

Original

How resistant are levodopa-resistant axial symptoms? Response of freezing, posture and voice to increasing levodopa intestinal infusion rates in Parkinson's disease / Imbalzano, G., Rinaldi, D., Calandra-Buonaura, G., Contin, M., Amato, F., Giannini, G., Sambati, L., Ledda, C., Romagnolo, A., Olmo, G., Cortelli, P., Zibetti, M., Lopiano, L., Artusi, C.A.. - In: EUROPEAN JOURNAL OF NEUROLOGY. - ISSN 1351-5101. - ELETTRONICO. - 30:1(2023), pp. 96-106. [10.1111/ene.15558]

Availability:

This version is available at: 11583/2971492 since: 2022-09-20T07:42:23Z

Publisher:

Wiley

Published

DOI:10.1111/ene.15558

Terms of use:

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)

Giannini Giulia (Orcid ID: 0000-0002-0499-3236)
Ledda Claudia (Orcid ID: 0000-0003-0839-932X)
Romagnolo Alberto (Orcid ID: 0000-0002-1312-1843)
Cortelli Pietro (Orcid ID: 0000-0002-3633-8818)
Zibetti Maurizio (Orcid ID: 0000-0002-2939-343X)
Artusi Carlo Alberto (Orcid ID: 0000-0001-8579-3772)

How resistant are levodopa-resistant axial symptoms?

Response of freezing, posture and voice to increasing levodopa intestinal infusion rates in Parkinson's disease

Gabriele Imbalzano (MD)^{1,2*}, Domiziana Rinaldi (MD)^{3*}, Giovanna Calandra-Buonaura (MD, PhD)^{4,5}, Manuela Contin, (PharmD)^{4,5}, Federica Amato, (MD)⁶, Giulia Giannini (MD, PhD)^{4,5}, Luisa Sambati (MD, PhD)^{4,5}; Claudia Ledda (MD)^{1,2}; Alberto Romagnolo (MD)^{1,2}; Gabriella Olmo, (MD, PhD)⁶, Pietro Cortelli (MD, PhD)^{4,5}, Maurizio Zibetti (MD, PhD)^{1,2}, Leonardo Lopiano (MD, PhD)^{1,2^}, Carlo Alberto Artusi (MD, PhD)^{1,2^}

*These authors equally contributed to the manuscript

^These authors equally contributed to the manuscript

Affiliations:

¹ Department of Neuroscience "Rita Levi Montalcini", University of Torino, Torino, Italy

² SC Neurologia 2U, AOU Città della Salute e della Scienza, Torino, Italy

³ Department of Neuroscience, Mental Health and Sense Organs (NESMOS), Sapienza University of Roma, Roma, Italy

⁴ IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

⁵ Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

⁶ Department of Control and Computer Engineering, Politecnico di Torino, 10129 Torino, Italy

Corresponding Author:

Dr. Maurizio Zibetti

Department of Neuroscience "Rita Levi Montalcini", University of Torino, Via Cherasco 15, 10126, Torino, Italy; SC Neurologia 2U, AOU Città della Salute e della Scienza, Torino, Italy

Phone number: +39 011670 9366 **Email:** maurizio.zibetti@unito.it

Key words: levodopa, axial symptoms, freezing of gait, posture, parkinson's disease

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1111/ene.15558](https://doi.org/10.1111/ene.15558)

This article is protected by copyright. All rights reserved.

Word count: 3972

Running Title: High levodopa doses for PD axial symptoms

Accepted Article

ABSTRACT

Background

Treatment of freezing of gait (FoG) and other Parkinson's disease (PD) axial symptoms is challenging. Systematic assessments of axial symptoms at progressively increasing levodopa doses are lacking. We sought to analyze the resistance to high levodopa doses of FoG, posture, speech, and altered gait features presenting in daily-ON therapeutic condition.

Methods

We performed a pre-post interventional study including patients treated with levodopa/carbidopa-intestinal-gel-infusion (LCIG) with disabling FoG in daily-ON condition. Patients were evaluated at their usual LCIG infusion rate (T1), and one hour after 1.5x (T2) and 2x (T3) increase of the LCIG infusion rate by quantitative outcome measures. The number of FoG episodes (primary outcome), posture, speech, and gait features were objectively quantified during a standardized test by a blinded rater. Changes in motor symptoms, dyskinesia, and plasma levodopa concentrations were also analyzed.

Results

We evaluated sixteen patients with a mean age of 69 ± 9.4 years and treated with LCIG for a mean of 2.2 ± 2.1 years. FoG improved in 83.3% of patients by increasing the levodopa doses. The number of FoG episodes significantly decreased (mean 2.3 at T1, 1.7 at T2, 1.2 at T3; $p:0.013$). Posture and speech features did not show significant changes, while stride length ($p:0.049$), turn duration ($p:0.001$), and turn velocity ($p:0.024$) significantly improved doubling the levodopa infusion rate.

Conclusions

In a short-term evaluation, the increase of LCIG dose can improve 'dopa-resistant' FoG and gait issues in most advanced PD patients with overall good control of motor symptoms in the absence of clinically significant dyskinesia.

1. INTRODUCTION

Freezing of gait (FoG) and other axial symptoms, encompassing disorders of speech, posture, gait and balance, dominate the advanced phases of Parkinson's disease (PD) and represent one of the major causes of patients' disability.¹ The management of these symptoms remains a challenge since their response to dopaminergic therapies is complex.²⁻³ FoG is typically correlated with OFF periods and shows a good response to levodopa; however, FoG and other axial symptoms tend to become dopa-resistant over time,⁴⁻⁶ being present also when the control of cardinal motor symptoms and fluctuations is adequate.

According to the response to levodopa, four different FoG conditions have been clinically described: "OFF-FoG", relieved by dopaminergic medications, "Pseudo-ON-FoG", appearing during a seemingly optimal ON state but improved by higher dopaminergic supply, "Unresponsive-FoG", present in both OFF and ON state, independently from changes in dopaminergic medication, and "ON-FoG", a rare type of FoG induced by dopaminergic medications.⁷⁻⁸ Despite these clinically derived concepts of FoG pathophysiology, studies aiming to systematically evaluate FoG response to progressively increasing levodopa doses are lacking.⁹ Similarly, other axial symptoms like postural abnormalities and speech impairment have an uncertain response to levodopa that current literature does not help to clarify.^{4-5,9-11,12}

We hypothesize that FoG and other axial symptoms presenting in the daily-ON condition in advanced PD patients could have in most cases a higher threshold for improvement than cardinal motor symptoms, relieved by higher doses of levodopa. Thus, in this study we evaluated PD patients treated with levodopa/carbidopa intestinal gel (LCIG) infusion to analyze the actual resistance to levodopa of FoG and other axial symptoms presenting in ON therapeutic condition by assessing their changes at progressively increased levodopa doses.

2. METHODS

2.1 Study population

Sixteen consecutively consenting PD patients treated with LCIG infusion continuously delivered via a percutaneous endoscopic gastrostomy with a jejunal extension (PEG-J) were recruited from the Movement Disorder Unit of the University of Torino (Italy) and Bologna (Italy) between April and October 2021. All patients had good control of motor fluctuations and a stable LCIG infusion dose for at least 3 months.

Inclusion criteria were idiopathic PD;¹³ Hoehn and Yahr (H&Y) score between 2 and 3 in ON therapeutic condition;¹⁴ a recent history of regular and disabling FoG in daily-ON condition. To further improve the probability of including patients showing episodes of FoG during the experimental evaluation, we also screened and selected among patients reporting regular daily FoG those reporting FoG episodes several times a day in the last month, according with a score of 1 on question 1 and score ≥ 2 on question 2 of the New Freezing of Gait Questionnaire [NFOGQ]).^{15 16}

Exclusion criteria were a diagnosis of severe cognitive decline according to a Mini-Mental State Examination (MMSE) score ≤ 18 ;¹⁷ previous evidence of severe adverse effects with high levodopa doses, such as psychosis, hallucinations, painful dyskinesia, severe orthostatic hypotension, digestive symptoms; inability to walk independently for 10 meters in therapeutic ON condition; ineffective control of motor complications (MDS-UPDRS IV ≥ 13);¹⁸ previous or concomitant conditions other than PD known to negatively affect gait, posture, or speech.

2.2 Study design

We performed a pre-post interventional study consisting of a systematic, quantitative, blinded evaluation of axial symptoms during a single session of progressively increased LCIG infusion rate. All patients were evaluated in the morning, after the morning bolus dose and at least 2 hours of LCIG infusion therapy at their usual dose. The assessment was performed in three consecutive different therapeutic regimens: T1, at the patient's usual LCIG continuous infusion rate (daily-ON); T2, one hour after 1.5x increase of the LCIG infusion rate; and T3, one hour after 2x increase of the LCIG infusion rate (Figure 1).

2.3 Endpoints

As primary endpoint, we assessed FoG improvement, defined as the blinded, video-assessed reduction in the count of FoG episodes during a video-recorded two-minute walk test (2MWT) performed at the usual infusion rate (T1) and after doubling the LCIG infusion rate (T3).

As secondary endpoints, we evaluated the T1-vs.-T3 improvement of: a) posture, objectively evaluated by the blinded software-based calculation of postural angles from standardized patient pictures; and b) speech, defined as changes in monopitch, monoloudness, pauses, and rate of speech timing evaluated by vocal analysis of recorded voices while performing standardized reading performances.

As exploratory endpoint, we analyzed gait parameters in a subgroup of 12 patients performing an instrumented 2MWT and Timed Up and Go (TUG) test by using validated inertial motion sensors (Opal, APDM).

2.4 Procedure

2.4.1 General evaluation of patients

Each patient was first evaluated for PD stage as per the H&Y score, FoG presence and impact as per the NFoG-Q,¹⁵ falls as per the Falls Efficacy scale (FES),¹⁹ PD symptoms and their fluctuations as per the MDS-UPDRS part I, II, III, and IV,¹⁸ axial score as per the sum of MDS-UPDRS items 3.1, 3.3, 3.9, 3.10-3.13,³ PD phenotype (tremor dominant, postural instability/gait difficulty, indeterminate),²⁰ dyskinesia as per the UDysRS part I-IV,²¹ cognitive performances as per the MMSE¹⁷ and the Montreal Cognitive Assessment (MoCA),²² and Levodopa Equivalent Daily Dose (LEDD) calculated according to a validated conversion table,²³ and with the more recent proposed LED conversions factors for opicapone and safinamide.²⁴

2.4.2 Evaluation of FoG episodes

A video-recorded 2MWT was conducted in adequate space to allow for a 10-meter walk, back and forth in a straight line and performing tight turnings. The camera was placed vertically on a tripod, facing the patient at an adequate distance to capture the entire patient's figure and allow for detection of all FoG episodes during the video assessment. A rater expert in movement disorders not involved in the clinical assessment used videos to rate the number of FoG episodes blinded for the patient's therapeutic condition.¹⁶ ²⁵ This evaluation was performed at T1, T2, and T3.

2.4.3 Evaluation of postural abnormalities

Six photos were taken for each patient to determine the angles of Forward Trunk Flexion/Lateral Trunk Flexion (FTF/LTF): two photos in the frontal plane (framing the posterior side of the body) and four in the sagittal plane (two framing on the right side and two on the left side of the body). The first of each pair of photos was captured with the patient in a relaxed standing posture and the second one during the best effort to maintain a straight posture. Photos were collected for postural evaluation as previously reported.²⁶ We measured the degrees of trunk flexion on the frontal and sagittal plane according to the following protocol: angles of FTF with lumbar fulcrum, FTF with

thoracic fulcrum, and LTF were calculated according to validated software-based methods using a free software (<http://www.neuroimaging.uni-kiel.de/NeuroPostureApp>).²⁷ This evaluation was performed at T1, T2, and T3.

2.4.4 Evaluation of speech

A reading performance with a phonetically balanced text was recorded in a quiet hospital room using a digital voice recorder.⁴ All speech samples were copied to a computer, edited into individual files and analyzed by a biomedical engineer blinded to the participants' therapeutic condition using an algorithm for speech analysis.²⁸ Vocal signals underwent a pre-processing step using software Praat (<https://www.fon.hum.uva.nl/praat/>). The recordings were firstly down-sampled to 16 kHz and a de-noising filter with Praat default hyper-parameters was applied to each signal; the signal amplitude was normalized in the range (0,1) to compensate the speaker-microphone distance. Initial and final silence regions were manually removed. Finally, we extracted 5 features characterized by high interpretability to describe speech samples. Measures from the entire vocal signal includes monoloudness - i.e., the standard deviation of the signal intensity - and timing measures to detect changes in the rhythmic organization of the speech²⁹ - i.e., the Number of Pauses (NP), the Duration of Pause Intervals (DPI), defined as the median duration of unvoiced intervals exceeding 30 ms, and the Rate of Speech Timing (RST), proposed to evaluate the capability of alternating voiced, unvoiced and paused regions.³⁰ After identifying and merging voiced regions, we evaluated the *monopitch*, - i.e, the standard deviation of the fundamental frequency.²⁹ This evaluation was performed at T1, T2, and T3.

2.4.5 Gait and balance analysis

Twelve patients underwent an additional explorative instrumented evaluation of gait and balance parameters using wearable inertial sensors (Opal, APDM) placed at multiple points in the upper and lower body (2 sensors attached on the feet, 2 at outer surface of the thighs, 1 at right hip joint, 1 on the sternum and 1 at lumbar level). The tasks consisted in a battery of standardized motion tests:

- 2MWT, as described in section 2.4.2;
- TUG test with subjects asked to stand up from a chair, walk 3 meters straight, turn around, walk back and sit down, at a comfortable pace;
- 360 degrees Turn Test with patients requires to start from standing, make a turn on their selves 360° clockwise and, as soon as they return to the initial position, 360° anticlockwise.

- Sway test with patients asked to remain in balance during an upright standing position for thirty seconds, with arms at rest and eyes closed.

This evaluation was performed at T1, T2, and T3.

2.4.6 Levodopa plasma levels

The pharmacokinetic-dynamic assessment of levodopa plasma concentration was performed for each patient by a blood venous sample (2 mL) drawn by an indwelling catheter at T1, and then at T2 and T3, 60 minutes after every change of the infusion rate. Blood specimens were collected and processed for plasma levodopa concentration as previously reported.³¹

2.4.7 Clinical scale assessment

Finally, severity of motor symptoms and dyskinesia were collected at T1, T2, and T3 by means of MDS-UPDRS part III and UDysRS part III and IV, and the Patient Global Impression of change (PGI-C) scale was used at T2 and T3 to evaluate the subjective patients' perception of improvement, stability or worsening of their clinical state.

2.5 Sample size calculation and statistical analysis

For the sample size calculation, we relied on a previous study with a similar experimental setting and the same outcome measure reporting an effect size of 1.1 on video-assessed episodes of FoG.¹⁶ Considering 80% power at 5% level of significance, we estimated that a sample size of 10 patients was sufficient to address the primary endpoint.

Descriptive statistics (mean \pm standard deviation) were used for continuous variables and frequency for categorical data. The non-parametric Friedman test was used to compare results at the 3 different therapeutic conditions and Bonferroni's correction for multiple comparisons was applied. All test reported were two-tailed and a p-value ≤ 0.05 was considered as statistically significant. Data were analyzed using the Statistical Package for the Social Sciences (SPSS 27, Chicago, IL).

The study conforms with World Medical Association Declaration of Helsinki principles, was approved by the local institutional review board 'Città della Salute e della Scienza di Torino', and all patients gave their written informed consent to participate to the study.

3. RESULTS

Sixteen PD patients (10 males, 6 females) with a mean age of 69 ± 9.4 years and treated with LCIG for a mean of 2.2 ± 2.1 years were enrolled in the study. LCIG infusion mean morning dose, continuous dose, and total dose were 7.6 ± 2.6 ml, 2.8 ± 0.9 ml/h, and 49.1 ± 14.6 ml respectively, with a mean of 15.1 ± 1.7 hours of daily infusion therapy. In addition to LCIG, eight patients were treated with dopamine agonists, two with amantadine, two with opicapone and one with safinamide. All demographic, clinical, and therapeutic data of the cohort are detailed in Table 1. All patients completed the 3 study phases. One patient could not complete the voice assessment due to very severe dysarthria.

Plasma levodopa concentrations showed a significant progressive increase at each study phase, with levodopa levels ranging from a mean of 3.2 ± 2.6 $\mu\text{g/ml}$ at T1 to 3.6 ± 2.7 $\mu\text{g/ml}$ at T2, and 4.6 ± 2.9 $\mu\text{g/ml}$ at T3 ($p<0.001$).

3.1 Changes in FoG episodes, postural angles, and speech

Considering that 12 patients showed at least one FoG episode at T1, the rate of patients with a reduction of FoG episodes was 75% at T2 ($n= 9/12$) and 83.3% at T3 ($n= 10/12$). Three patients showed an increase of FoG episodes at T2 and one patient at T3.

On average, we observed in the entire cohort of 16 patients a significant progressive improvement of FoG episodes at each study phase ($p:0.013$), ranging from a mean of 2.3 ± 2.3 at T1 to 1.7 ± 2.3 at T2 and 1.2 ± 2.2 at T3 (Table 2, Figure 2).

Regarding posture, we found no significant improvement in relaxed nor in straight standing position for lumbar FTF ($p:0.164$ relaxed; $p:0.725$ straight), thoracic FTF ($p:0.819$ relaxed; $p:0.121$ straight), and LTF ($p:0.74$ relaxed; $p:0.195$ straight) at different infusion rates (Table 2). No significant differences were found also regarding speech parameters, namely monopitch ($p:0.570$), monoloudness ($p:0.247$), NP ($p:0.766$), DPI ($p:0.766$), RST ($p:0.155$) (Table 2).

3.2 Motor symptoms, dyskinesia and patient global impression

Motor symptoms evaluated by the MDS-UPDRS part III did not show statistically significant changes from T1 to T3 ($p:0.091$), with scores ranging from a mean of 31.7 ± 11.7 at T1 to 29 ± 11.7 at T2 and 27.3 ± 13.4 at T3. Similarly, the axial score showed a slight improvement from a mean of

8.8±3.3 at T1 to 8.1±3.6 at T2, and 7.9±3.9 at T3 in the absence of a statistically significant difference (p:0.159).

Dyskinesia showed a significant increase between T1 and T3, with UDysRS part III ranging from a mean of 7.1±5 at T1 to 7.6±4.4 at T2 and 9.4±5 at T3 (p:0.005), and UDysRS part IV from 5.4±3.0 at T1 to 5.9±3.2 at T2, and 6.6±4 at T3 (p:0.001) (Figure 3).

Regarding patient's impression of treatment efficacy, the self-administered PGI-C score at T3 reported 8 cases of improvement from T1 (score <4), 3 cases of no change (score =4), and 5 cases of worsening (score >4). The mean PGI-C score was 3.9±1 at T2 and 3.8±1.3 at T3.

No significant side effects were observed during the study, with the exception of two cases of discomfort due to transient nausea and lipothymia not preventing the completion of the study protocol. Additionally, one patient experienced an episode of fall during the 2MWT.

3.3 Exploratory analysis of gait and balance

Twelve patients underwent gait and balance analysis using wearable inertial sensors. Significant improvements were observed between T1 and T3 for stride length during the 2MWT (p:0.049), turn duration (p:0.001) and turn velocity during the TUG test (p:0.024). A trend of improvement between T1 and T3 were found for gait speed and double support during the 2MWT, for turn angle during the TUG test, and for turn velocity during the 360 degrees turn test; step duration during the 2MWT, sit to stand duration during the TUG test, and sway area and acceleration showed a trend of worsening without reaching statistical significance (Table 3).

4. DISCUSSION

In this study, we quantitatively analyzed the response of FoG, posture, and speech to increased levodopa doses in 16 LCIG-treated PD patients presenting disabling axial symptoms despite good control of cardinal motor symptoms and fluctuations. FoG episodes, quantified by a movement disorder expert blinded for the therapeutic condition, significantly improved after doubling the levodopa infusion rate, while the objective analysis of posture and speech did not show significant changes. Gait analysis, performed in a subgroup of 12 patients, showed a significant improvement in stride length, turn duration and turn velocity after doubling the levodopa infusion rate. As expected, the MDS-UPDRS part III score did not differ in the 3 therapeutic conditions since all patients had good control of main motor symptoms in the daily-On condition. Dyskinesia showed mild yet statistically significant worsening from T1 to T3, with UDysRS part III scores ranging from 7.1 to 9.4; the change we observed was below the threshold of 2.7 points to discriminate a

clinically important worsening of dyskinesia,³² and the therapy increase was well tolerated in all patients, except for two cases of transient malaise.

To our knowledge, the response of FoG to progressively increased levodopa doses has never been systematically investigated, and data provided in our study offer an experimental validity to the hypothesis of the existence of 4 different FoG types clinically described so far, namely “OFF-FoG”, “Pseudo-ON-FoG”, “Unresponsive-FoG”, and “ON-FoG”.^{7 8} In our study, the number of FoG episodes improved in all but two patients with a two-fold increase of the LCIG infusion rate. The two patients who did not improve doubling the infusion rate showed substantial differences: one patient improved from T1 to T2 (from 4 to 0 FoG episodes) and then worsened from T2 to T3 (from 0 to 4 FoG episodes); the other patient showed a linear increase in FoG episodes from T1 to T3 (4 episodes at T1, 6 at T2 and 8 at T3) (Figure 2).

These data suggest that, in most advanced patients treated with LCIG, episodes of FoG presenting in a practical daily-ON condition can benefit from an increase in the levodopa dose, pointing toward a relative rather than an absolute FoG resistance to levodopa. Conversely, in a few cases, our data support the hypothesis of the existence of rare cases of FoG induced by high doses of levodopa, with a different threshold for each patient.

A role of maladaptive plasticity caused by long-term levodopa treatment, resulting in a mismatch between under-stimulated motor loops and activated non-motor loops, could be implicated in the difficulty to manage axial symptoms in advanced PD phases, so that increasingly higher dopamine concentrations are required to overcome thresholds of postsynaptic receptors within the motor circuitry.³³ Thus, a new activation of aberrant loops could be overcome by a substantial increase in the dopaminergic dose or by a different type of stimulation of the dopaminergic networks (e.g., deep brain stimulation or LCIG). In fact, a certain degree of efficacy in treating FoG by continuous dopaminergic stimulation has already been described as superior to the pulsatile effect typical of oral therapy even in absence of significant dose changes.^{34 35 36}

Another interesting hypothesis is the existence of a fifth FoG type, the so-called “Triphasic-ON” FoG, arising in both “ON” and “supra-ON” states, but with the presence of a narrow “ON” therapeutic window in the transition between these two states where FoG improves, difficult to achieve with oral therapy due to the unpredictability of actual levodopa plasma levels.⁹

In parallel with the improvement of FoG, the gait analysis in our study demonstrated an improvement of stride length, turn duration, and turn velocity, confirming the strict relationship between FoG and specific gait parameters^{37 38 39} and supporting the theory of a higher threshold for the improvement of axial motor symptoms when compared with appendicular symptoms like limb tremor, rigidity, and bradykinesia.

Despite a small trend in postural angles, our study suggests that other axial symptoms like postural abnormalities and speech impairment cannot be satisfactorily improved (at least acutely) by increasing the levodopa dose in patients with already adequate control of motor symptoms and fluctuations. The complex multilevel dysfunction underlying postural abnormalities (i.e., abnormal sensory-motor integration, cognitive dysfunctions, musculoskeletal system involvement) could explain the scarce improvement early after the change of therapeutic doses and should be probably better analyzed after a few days of treatment at increased levodopa doses.^{40 41} Interestingly, previous studies did not show any difference in terms of posture angles also after chronic treatment with LCIG,⁴² making the treatment of these symptoms a real challenge and providing clues for a different physiopathology among different axial symptoms. Likely, the analysis of speech did not show significant differences in the three study phases. No data about the effect of the LCIG therapy on speech are currently available, and evidence about oral levodopa indicates various and unpredictable modifications in phonation and language articulation in mild to moderate PD both in the short and long term.^{43 44} Current data on oral levodopa treatment proved a great variability of speech alteration profile, rendering it difficult to understand the role of levodopa on speech in PD. At a group level, a trend toward a greater improvement in phonation and articulation can be observed with levodopa treatment, especially in the early stages of the disease⁴⁴. In later disease stages, the role of non-dopaminergic mechanisms on speech, particularly prosody and fundamental frequency variability, could be more prominent and justify the mixed literature results on the effect of dopaminergic therapy on speech^{45 46}. Likely, our study on advanced PD patients proved a high heterogeneity in baseline and dose-augmented assessments, indicating variable improvement and worsening of different speech parameters depending from patient to patient, thus preventing the observation of a group trend toward an efficacy of higher LCIG infusion rates on speech. On the other hand, studies including STN-DBS treated patients showed that the benefit on motor symptoms provided by the chronic stimulation is typically not associated with improvement of speech, which rather may deteriorate as a consequence of increased dysarthria due to the current spreading to adjacent areas, such as the corticobulbar tract or pallidofugal and cerebellar fibers.⁴⁵

The limitations of this work are mainly related to the lack of a long-term evaluation of the efficacy and tolerability of high doses of levodopa to overcome axial symptoms, and the relatively small sample size, adequate for the assessment of FoG episodes but probably not sufficient to disclose possible significant differences in posture and speech, also considering the heterogeneous presentation of these symptoms in our cohort. Moreover, due to difficulties in patients' access and assessment reliability, we could not evaluate patients in Off condition after an overnight

Accepted Article

withdrawal of dopaminergic therapy. This information would have allowed quantifying the response to levodopa with the standard infusion rate. Finally, this study analyzed a specific cohort of PD patients presenting an advanced disease stage treated with LCIG and a heterogeneous cognitive profile. These aspects should be carefully considered for the generalizability of our findings to all PD patients. Finally, the progressive increase of levodopa gel infusion during the same session did not guarantee a perfectly matched increase in plasma levodopa concentrations among patients and an accumulation effect from running the three assessments in a single session cannot be ruled out; to have a more precise knowledge of the pharmacokinetic effect of our progressive levodopa dose increase, we analyzed plasma levodopa concentrations immediately before the start of each assessment (at baseline and 1 hour after every infusion rate increase), finding moderate inter-subject variability but also a statistically significant increase of concentrations at a group level.

These shortcomings notwithstanding, we demonstrated that in most cases of advanced PD treated with LCIG with good control of motor symptoms, the increase in the levodopa plasma concentrations can improve FoG, suggesting that the Pseudo-ON-FoG could be the most common FoG type in these patients. While the increase of levodopa doses could be a viable option to overcome apparently dopa-resistant FoG, our findings do not endorse the attempt of increasing levodopa for treating postural and speech abnormalities when the control of other symptoms is adequate. We cannot recommend the practice of an increase of LCIG doses to overcome FoG episodes according to data provided by our clinical trial due to the limited time of the assessment with high LCIG infusion rates. However, the proof of improving FoG episodes provided by higher plasma levodopa concentrations should foster new clinical studies to evaluate the long-term tolerance and efficacy of higher levodopa or LCIG doses in patients with apparently dopa-resistant FoG. Accordingly, in patients treated with LCIG with severe FoG, the use of 'on-demand' extra doses in specific moments when they need better walking performance or when they are experiencing invalidating FoG episodes could be an interesting option to explore.

Pending further studies with larger sample size and prolonged follow-up and considering the low generalizability of our findings, which are related to a subgroup of advanced PD patients treated with LCIG and with different clinical and cognitive issues, we believe that this study indicates the existence of a higher threshold for the efficacy of levodopa on FoG than on cardinal motor symptoms in advanced PD. An approach based on the increase of levodopa doses in therapeutically optimized patients with a seeming 'Unresponsive-FoG' is worth further exploring.

DECLARATION

Acknowledgment

We thank the patients and their families for participating in this study.

Funding

The authors have not declared a specific grant for this research.

Conflict of interest

Disclosures: none.

Contributors

GI and DR: conceptualization; data curation; formal analysis; investigation; visualization; writing – original draft preparation. GCB, MC, FA, GG and LS execution; resources; data curation; validation; writing -original draft preparation. CL, AR, and GO formal analysis; review and critique; PC and MZ methodology; organization. LL and CAA conceptualization; resources; project administration; supervision; validation; writing – review & editing. All authors reviewed the manuscript, provided critical comments to improve the draft, and approved the final version of the manuscript.

Conflicting interests

GI reports no financial disclosures. DR reports no financial disclosures. GCB reports no financial disclosures. MC reports no financial disclosures. FA reports no financial disclosures. GG reports no financial disclosures. LS reports no financial disclosures. CL received travel grants from Bial and Merz. AR received travel grants from Chiesi Farmaceutici, speaker honoraria from Bial. GO reports no financial disclosures. PC reports no financial disclosures. MZ has received honoraria for lecturing and travel grants from Medtronic, Bial Pharma, and AbbVie. LL has received honoraria for lecturing and travel grants from Medtronic, UCB Pharma, and AbbVie. CAA has received honoraria from Ralparma and Zambon for scientific support, and speaker honoraria from Ecupharma and Bial.

Data availability statement

The data that support the findings of this study are available in anonymized dataset from the corresponding author, upon reasonable request.

Accepted Article

REFERENCES

- 1 Fasano A, Aquino CC, Krauss JK, et al. Axial disability and deep brain stimulation in patients with Parkinson disease. *Nat Rev Neurol*. 2015;11:981-110.
- 2 Lau B, Meier N, Serra G, et al. Axial symptoms predict mortality in patients with Parkinson disease and subthalamic stimulation. *Neurology*. 2019;92:e2559-e2570.
- 3 Bouça-Machado R, Pona-Ferreira F, Gonçalves N, et al. CNS Multidisciplinary Team. Outcome measures for evaluating the effect of a multidisciplinary intervention on axial symptoms of Parkinson's disease. *Front Neurol*. 2020;11:328.
- 4 Fabbri M, Guimarães I, Cardoso R, et al. Speech and voice response to a levodopa challenge in late-Stage Parkinson's disease. *Front Neurol*. 2017;8:432.
- 5 Kataoka H, Ueno S. Can postural abnormality really respond to levodopa in Parkinson's disease? *J Neurol Sci*. 2017;377:179-184.
- 6 Fabbri M, Coelho M, Abreu D, et al. Do patients with late-stage Parkinson's disease still respond to levodopa? *Parkinsonism Relat Disord*. 2016;26:10-16.
- 7 Espay AJ, Fasano A, van Nuenen BF, et al. "On" state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication. *Neurology*. 2012;78:4547.
- 8 Nutt JG, Bloem BR, Giladi N, et al. Freezing of gait: moving forward on a mysterious clinical phenomenon. *Lancet Neurol*. 2011;10:734-744.
- 9 Morales-Briceño H, Tsui D, Griffith J, et al. "On-State" Freezing of Gait: Insights and Treatment With Levodopa Intestinal Gel Infusion. *Mov Disord*. 2020;35:895-896.
- 10 Cui CK, Lewis SJG. Future Therapeutic Strategies for Freezing of Gait in Parkinson's Disease. *Front Hum Neurosci*. 2021;15:741918.
- 11 Srivanitchapoom P, Hallett M. Camptocormia in Parkinson's disease: definition, epidemiology, pathogenesis and treatment modalities. *J Neurol Neurosurg Psychiatry*. 2016;87:75-85.

- 12 Roediger J, Artusi CA, Romagnolo A, et al. Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis. *Parkinsonism Relat Disord.* 2019;62:122-127.
- 13 Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord.* 2015;30:1591-1601.
- 14 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology.* 1967;17:427-442.
- 15 Nieuwboer A, Rochester L, Herman T, et al. Reliability of the new freezing of gait questionnaire: agreement between patients with Parkinson's disease and their carers. *Gait Posture.* 2009;30:459-463.
- 16 Barthel C, Nonnekes J, van Helvert M, et al. The laser shoes: A new ambulatory device to alleviate freezing of gait in Parkinson disease. *Neurology.* 2018;90:e164-e171.
- 17 Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. *Mov Disord.* 2007;22:1689-1707.
- 18 Martínez-Martín P, Rodríguez-Blázquez C, Mario Alvarez, et al. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale. *Parkinsonism Relat Disord.* 2015;21:50-54;.
- 19 Mehdizadeh M, Martinez-Martin P, Habibi SA, et al. Reliability and Validity of Fall Efficacy Scale-International in People with Parkinson's Disease during On- and Off-Drug Phases. *Parkinsons Dis.* 2019;2019:6505232.
- 20 Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. *Mov Disord.* 2013;28:668-670.
- 21 Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. *Mov Disord.* 2008;23:2398-2403.

- 22 Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. *Neurology*. 2009;73:1738-1745.
- 23 Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov Disord*. 2010;25:2649-2653.
- 24 Schade S, Mollenhauer B, Trenkwalder C. Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide. *Mov Disord Clin Pract*. 2020;7:343-345.
- 25 Morris TR, Cho C, Dilda V, et al. A comparison of clinical and objective measures of freezing of gait in Parkinson's disease. *Parkinsonism Relat Disord*. 2012;18:572-577.
- 26 Tinazzi M, Gandolfi M, Ceravolo R, et al. Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. *Mov Disord Clin Pract*. 2019;6:576-585.
- 27 Margraf NG, Wolke R, Granert O, et al. Consensus for the measurement of the camptocormia angle in the standing patient. *Parkinsonism Relat Disord*. 2018;52:1-5.
- 28 Amato F, Borzi L, Olmo G, et al. An algorithm for Parkinson's disease speech classification based on isolated words analysis. *Health Inf Sci Syst*. 2021;9:32.
- 29 Ruz J, Tykalová T, Novotný M, et al. Distinct patterns of speech disorder in early-onset and late-onset de-novo Parkinson's disease. *NPJ Parkinsons Dis*. 2021;7:98.
- 30 Ruz J, Tykalova T, Ramig LO, et al. Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders. *Mov Disord*. 2021;36:803-814.
- 31 Baruzzi A, Contin M, Albani F, et al. Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection. *J Chromatogr*. 1986;375:165-169
- 32 Mestre TA, Beaulieu-Boire I, Aquino CC, et al. What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease? *Parkinsonism Relat Disord*. 2015;21:1349-1354.

- 33 Nonnekes J, Bereau M, Bloem BR. Freezing of Gait and Its Levodopa Paradox. *JAMA Neurol.* 2020;77:287-288.
- 34 Zibetti M, Angrisano S, Dematteis F, et al. Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease. *J Neurol Sci.* 2018;385:105-108.
- 35 Cossu G, Ricchi V, Pilleri M, et al. Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait. *Neurol Sci.* 2015;36:1683-1686.
- 36 Rispoli V, Golfrè Andreasi N, Penna G, et al. Levodopa/Carbidopa Intestinal Gel Infusion Therapy: Focus on Gait and Balance. *Mov Disord Clin Pract.* 2018;5:542-545.
- 37 Chee R, Murphy A, Danoudis M, et al. Gait freezing in Parkinson's disease and the stride length sequence effect interaction. *Brain.* 2009;132(Pt 8):2151-2160.
- 38 Nieuwboer A. Cueing for freezing of gait in patients with Parkinson's disease: a rehabilitation perspective. *Mov Disord.* 2008;23 Suppl 2:S475-481.
- 39 Diep C, O'Day J, Kehnemouyi Y, et al. Gait Parameters Measured from Wearable Sensors Reliably Detect Freezing of Gait in a Stepping in Place Task. *Sensors (Basel).* 2021;21(8):2661; doi: 10.3390/s21082661.
- 40 Tinazzi M, Geroin C, Gandolfi M, et al. Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management. *Mov Disord.* 2016;31:1785-1795.
- 41 Doherty KM, van de Warrenburg BP, Peralta MC, et al. Postural deformities in Parkinson's disease. *Lancet Neurol.* 2011;10:538-549.
- 42 Fabbri M, Pongmala C, Artusi CA, et al. Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson's disease. *Neurol Sci.* 2020;41:1927-1930.
- 43 Ho AK, Bradshaw JL, Iansek R. For better or worse: The effect of levodopa on speech in Parkinson's disease. *Mov Disord.* 2008;23:574-580.
- 44 Skodda S, Visser W, Schlegel U. Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease. *J Neural Transm (Vienna).* 2010;117:197-205.

- 45 Skodda S, Flasskamp A, Schlegel U. Instability of syllable repetition in Parkinson's disease—
influence of levodopa and deep brain stimulation. *Mov Disord.* 2011;26:728-730.
- 46 Skodda S, Grönheit W, Schlegel U. Intonation and speech rate in Parkinson's disease:
general and dynamic aspects and responsiveness to levodopa admission. *J Voice.*
2011;25:e199-205.

FIGURE LEGENDS

Figure 1. Flow chart of the assessment performed.

NFoG-Q: New Freezing of Gait Questionnaire; MMSE: Mini Mental Examination State; MOCA: Montreal Cognitive Assessment; FES: Falls Efficacy Scale; MDS-UPDRS: Movement Disorder Society - Unified Parkinson's Disease Rating Scale; UDysRS: Unified Dyskinesia Rating Scale; LEDD: Levodopa equivalent daily dose; LCIG: Levodopa-Carbidopa Intestinal Gel; PGI-C: Patient Global Impression of change

Figure 2. FoG episodes for each patient at different timepoints

T1, patient's usual LCIG continuous infusion rate (daily-ON); T2, one hour after 1.5x increase of the LCIG infusion rate; T3, one hour after 2x increase of the LCIG infusion rate

Figure 3. Motor, axial and dyskinesia score

T1, patient's usual LCIG continuous infusion rate (daily-ON); T2, one hour after 1.5x increase of the LCIG infusion rate; T3, one hour after 2x increase of the LCIG infusion rate

TABLES

Table 1. Demographic and clinical features of enrolled patients

Gender (males/females)	10/6 (62,5%/37,5%)
Age (years)	69.0 ± 9.4 (57-80)
Age at onset of disease (years)	52.8 ± 8.9 (36-63)
Disease duration (years)	15.9 ± 6.6 (8-28)
LCIG duration (years)	2.2± 2.1 (1-8)
Clinical phenotype (n)(%)	
<i>PIGD</i>	8 (50%)
<i>Tremor dominant</i>	2 (12.5%)
<i>Indeterminate</i>	6 (37.5%)
LEDD (mg)	1317.9 ± 296.2 (885.3-1992.8)
LCIG infusion	
<i>Morning dose (ml)</i>	7.6 ± 2.6 (0-11)
<i>Continuous dose (ml/h)</i>	2.8 ± 0.9 (1.6-4.6)
<i>Total daily dose (ml)</i>	49.1 ± 14.6 (29.6-80)
MMSE	25.4 ± 3.1 (19-30)
MoCA	21.4 ± 4.1 (15-28)
New Freezing Of Gait – Questionnaire	18.6 ± 5.9 (10-31)
Falls Efficacy Scale	32.6 ± 18.4 (10-73)
MDS-UPDRS-I score	10.5 ± 5.0 (0-20)
MDS-UPDRS-II score	17.3 ± 5.0 (10-30)
MDS-UPDRS-IV score	8.5 ± 2.9 (3-12)
MDS-UPDRS item 4.1	2.1 ± 1.4 (0-4)
MDS-UPDRS item 4.2	1.3 ± 0.8 (0-2)
MDS-UPDRS item 4.3	1.5 ± 0.6 (1-3)
MDS-UPDRS item 4.4	1.5 ± 0.8 (0-3)

UDysRS-I total score	13.6 ± 8.4 (0-25)
UDysRS-II total score	5.3 ± 3.0 (0-9)

Results are reported as average ± standard deviation (*range*) or absolute values (*percentage*), as appropriate. PIGD: Postural Instability/Gait Difficult; MMSE: Mini Mental State Examination; MoCA: Montreal Cognitive Assessment; LEDD: Levodopa equivalent daily dose; LCIG: Levodopa-Carbidopa Intestinal Gel; MDS-UPDRS: Movement Disorder Society - Unified Parkinson's Disease Rating Scale; UDysRS: Unified Dyskinesia Rating Scale

Table 2. Axial symptoms outcomes

		T1	T2	T3	P value
Freezing of gait	Number of episodes	2.3 ± 2.3	1.7 ± 2.3	1.2 ± 2.2	0.013
	Type of episodes*	0.1±0.3 start 2.2±2.2 turn 0 linear	0.1±0.3 start 1.4±2 turn 0.2±0.8 linear	0.1±0.2 start 0.7±1 turn 0.4±1.5 linear	<i>n.a.</i>
	Pattern of episodes*	1.8±1.7 trembling 0.3±0.5 shuffling 0.3±0.6 akinesia	1.3±1.9 trembling 0.2±0.5 shuffling 0.3±0.8 akinesia	0.6±0.9 trembling 0.2±0.8 shuffling 0.4±1.1 akinesia	<i>n.a.</i>
Posture	LTF relaxed (°)	7.0 ± 15.5	6.3 ± 13.3	6.1 ± 12.2	<i>0.74</i>
	LTF straight (°)	3.9 ± 8.5	4.9 ± 10.9	4.6 ± 9.2	<i>0.195</i>
	Thoracic FTF relaxed (°)	44.0 ± 10.3	43.4 ± 7.5	43.0 ± 10.6	<i>0.819</i>
	Lumbar FTF relaxed (°)	13.9 ± 14.5	13.3 ± 14.2	13.5 ± 17.0	<i>0.164</i>
	Thoracic FTF straight (°)	39.3 ± 8.6	41.3 ± 7.4	39.1 ± 7.2	<i>0.121</i>
	Lumbar FTF straight (°)	11.0 ± 11.8	10.8 ± 12.0	11.0 ± 12.9	<i>0.725</i>
Speech	Monopitch (Hz)	40.9 ± 27.2	48.3 ± 28.7	43.9 ± 30.5	<i>0.57</i>

Monoloudness (dB)	15.0 ± 3.9	15.0 ± 3.5	15.6 ± 3.1	0.247
Number of pauses	242.1 ± 77.7	243.1 ± 85.3	233.6 ± 75.9	0.766
DPI (ms)	0.1 ± 0.2	0.1 ± 0.02	0.1 ± 0.1	0.766
RST (intervals/min)	0.3 ± 0.1	0.3 ± 0.1	0.3 ± 0.1	0.155
MDS-UPDRS 3.1 item (speech)	1.6 ± 0.7	1.7 ± 0.7	1.4 ± 0.6	0.039


Results are reported as average ± standard deviation. LTF: Lateral Trunk Flexion; FTF: Forward Trunk Flexion; DPI: Duration of pause intervals; RST: Rate of Speech Timing. *na*: not applicable.

* Types and patterns of freezing of gait episodes have been reported based on video analysis according to the classification proposed in reference 8.

Table 3. Gait and balance exploratory analysis

	T1	T2	T3	P value
2MWT - Gait speed (m/s)	0.7 ± 1.6	0.7 ± 0.2	0.7 ± 0.2	0.205
2MWT - Double support (%GCT)	26.4 ± 6	26.2 ± 5.8	25.6 ± 5.5	0.125
2MWT - Step duration (s)	0.6 ± 0.1	0.6 ± 0.1	0.6 ± 0.1	0.717
2MWT - Stride Length (m)	0.8 ± 0.2	0.9 ± 0.2	0.9 ± 0.2	0.049
TUG - Duration (s)	16.3 ± 3.6	17.6 ± 4.6	17.3 ± 8.1	0.297
TUG - Angle (°)	175.8 ± 7.2	168.8 ± 7.9	156.8 ± 36.6	0.064
TUG - Turn duration (s)	2.9 ± 0.5	2.6 ± 0.5	2.4 ± 0.5	0.001
TUG - Turn velocity (m/s)	132.2 ± 25.7	148.1 ± 41.8	156.5 ± 59.9	0.024
TUG - Sit to stand duration (s)	1 ± 0.2	1.2 ± 0.6	1.2 ± 0.7	0.558
360° - Turn duration (s)	5.0 ± 1.5	4.7 ± 1.5	4.3 ± 1.0	0.076
360° - Turn velocity (m/s)	119.3 ± 37.8	127.2 ± 26.3	131.7 ± 36.0	0.455
Sway - Area (m²)	20.1 ± 34.6	26.0 ± 36.0	32.2 ± 43.2	0.105
Sway - Acceleration (m²/s⁴)	0.6 ± 1.0	0.8 ± 1.1	0.9 ± 1.2	0.105

Results are reported as average ± standard deviation. 2MWT: Two-minute walk test; GCT: Gait cycle time; TUG: Timed up and go.




- NFOG-Q
- MMSE
- MoCA
- FES
- MDS-UPDRS part I, II and IV
- UDysRS part I and II
- LEDD calculation

- Ldopa plasmatic concentration
- FoG assessment
- Posture assessment
- Speech performance
- Gait analysis
- MDS-UPDRS part III
- UDyRS part III and IV


- Ldopa plasmatic concentration
- FoG assessment
- Posture assessment
- Speech performance
- Gait analysis
- MDS-UPDRS part III
- UDyRS part III and IV
- PGC-I

- Ldopa plasmatic concentration
- FoG assessment
- Posture assessment
- Speech performance
- Gait analysis
- MDS-UPDRS part III
- UDyRS part III and IV
- PGC-I

ENE_15558_Figure 1 - Flow chart.tiff



ENE_15558_Figure 2 - ex 4.tiff



ENE_15558_Figure 3 - Motor axial and dyskinesia score.tiff

MANAGE-PD

Tool for Making Informed Decisions to
Aid Timely Management of Parkinson's Disease

MANAGE-PD allows you to:

- Identify PD patients inadequately controlled on oral medications
- Determine which patients with PD may be adequately controlled on their current treatment regimen or may require changes to their treatment regimen



Scan the QR code to
access to the web

Click here to
access to the web



MANAGE-PD is an AbbVie Inc. registered Medical Device. It is a collaborative research and development effort between AbbVie Medical Affairs and Health Economics and Outcomes, the Parkinson's Foundation and an international panel of Movement Disorder Specialists.

©2022 AbbVie Inc. All rights reserved. The Parkinson's Foundation logo is the sole property of the Parkinson's Foundation used with written permission. Any use of the Parkinson's Foundation name or logo without Foundation permission is prohibited. All content in <https://www.managepd.eu/> is intended only for informational use by healthcare professionals and is not offered as or intended to be medical advice for any particular patient. This information is not intended for patients. Only a healthcare professional exercising independent clinical judgement can make decisions regarding appropriate patient care and treatment options considering the unique characteristics of each patient.

PD: Parkinson's Disease